Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable metal stent for biliary drainage during neoadjuvant therapy in patients with pancreatic cancer with obstructive jaundice (PUN-NAC trial).
adult gastroenterology
endoscopy
pancreatic disease
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
08 07 2021
08 07 2021
Historique:
entrez:
10
7
2021
pubmed:
11
7
2021
medline:
5
8
2021
Statut:
epublish
Résumé
Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy (NAC/NACRT) for resectable/borderline resectable pancreatic cancers was recently performed to improve clinical outcomes and led to good results, although it remains controversial whether NAC/NACRT is beneficial for resectable pancreatic cancer. A few recent studies revealed longer patency and lower cost related to the stent occlusion of a metal stent than those of a plastic stent during NAC/NACRT. It also remains controversial which type of self-expandable metal stent (SEMS) is the most suitable for patients with resectable/borderline resectable pancreatic cancer during NAC/NACRT: an uncovered SEMS (USEMS), a fully covered SEMS (FCSEMS) or a partially covered SEMS (PCSEMS). So far, two randomised controlled trials indicated that a USEMS and an FCSEMS were similar in preoperative stent dysfunction and adverse event rate. Thus, we aimed to verify the non-inferiority of a PCSEMS to a USEMS in this multicentre randomised controlled trial. We designed a multicentre randomised controlled trial, for which we will recruit 100 patients with resectable/borderline resectable pancreatic cancer and distal biliary obstruction scheduled for NAC/NACRT from 13 high-volume institutions. Patients will be randomly allocated to the PCSEMS group or USEMS group. The primary outcome measure is the preoperative biliary event rate. Data will be analysed after completion of the study. We will calculate the 95% CIs of the incidence of preoperative biliary events in each group and analyse whether the difference between them is within the non-inferiority margin (10%). This study has been approved by the institutional review board of Hokkaido University Hospital. The results will be submitted for presentation at an international medical conference and published in a peer-reviewed journal. UMIN000041737; jRCT1012200002.
Identifiants
pubmed: 34244257
pii: bmjopen-2020-045698
doi: 10.1136/bmjopen-2020-045698
pmc: PMC8268904
doi:
Banques de données
UMIN-CTR
['UMIN000041737']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e045698Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):17-30
pubmed: 29032610
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Front Oncol. 2020 Feb 28;10:245
pubmed: 32185128
Surg Endosc. 2011 Feb;25(2):613-8
pubmed: 20632189
Am J Gastroenterol. 2017 Feb;112(2):260-273
pubmed: 27845340
J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54
pubmed: 29032636
World J Surg. 2019 Feb;43(2):642-648
pubmed: 30298284
BMC Gastroenterol. 2017 Oct 11;17(1):105
pubmed: 29020933
J Gastrointest Oncol. 2012 Dec;3(4):309-13
pubmed: 23205306
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):606-617
pubmed: 31306735
Dig Endosc. 2015 Jan;27(2):259-64
pubmed: 25209944
Lancet. 2015 Mar 28;385(9974):1206-18
pubmed: 25479696
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
Gut Liver. 2020 Mar 15;14(2):269-273
pubmed: 31060118
Gastroenterol Res Pract. 2016;2016:7968201
pubmed: 26880897
Eur J Cancer. 2017 Jul;79:41-49
pubmed: 28460245
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Dig Dis Sci. 2018 Sep;63(9):2466-2473
pubmed: 29218484
Am J Gastroenterol. 2013 Jul;108(7):1168-73
pubmed: 23545711
Am J Surg. 2014 Jul;208(1):1-10
pubmed: 24530042
Surg Today. 2016 Jun;46(6):668-85
pubmed: 26289837
Nat Rev Clin Oncol. 2015 Jun;12(6):319-34
pubmed: 25824606
Gastrointest Endosc. 2019 Oct;90(4):602-612.e4
pubmed: 31276674
Gastrointest Endosc. 2016 Sep;84(3):460-6
pubmed: 26972022
Gut. 2016 Dec;65(12):1981-1987
pubmed: 26306760